These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 37522338)

  • 21. Does TRIPS (Agreement on Trade-Related Aspects of Intellectual Property Rights) prevent COVID-19 vaccines as a global public good?
    Haugen HM
    J World Intellect Prop; 2021 Jul; 24(3-4):195-220. PubMed ID: 34230807
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Industry influence over global alcohol policies via the World Trade Organization: a qualitative analysis of discussions on alcohol health warning labelling, 2010-19.
    Barlow P; Gleeson D; O'Brien P; Labonte R
    Lancet Glob Health; 2022 Mar; 10(3):e429-e437. PubMed ID: 35120586
    [TBL] [Abstract][Full Text] [Related]  

  • 23. WTO confidential: the case of asbestos. World Trade Organization.
    Castleman B
    Int J Health Serv; 2002; 32(3):489-501. PubMed ID: 12211289
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Implications of bilateral free trade agreements on access to medicines.
    Correa CM
    Bull World Health Organ; 2006 May; 84(5):399-404. PubMed ID: 16710551
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Impact of the World Trade Organization TRIPS agreement on the pharmaceutical industry in Thailand.
    Supakankunti S; Janjaroen WS; Tangphao O; Ratanawijitrasin S; Kraipornsak P; Pradithavanij P
    Bull World Health Organ; 2001; 79(5):461-70. PubMed ID: 11417042
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Medicine procurement and the use of flexibilities in the Agreement on Trade-Related Aspects of Intellectual Property Rights, 2001-2016.
    't Hoen EF; Veraldi J; Toebes B; Hogerzeil HV
    Bull World Health Organ; 2018 Mar; 96(3):185-193. PubMed ID: 29531417
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The right to health and medicines: the case of recent multilateral negotiations on public health, innovation and intellectual property.
    Velasquez G
    Dev World Bioeth; 2014 Aug; 14(2):67-74. PubMed ID: 24813066
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Addressing legal and political barriers to global pharmaceutical access: options for remedying the impact of the Agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPS) and the imposition of TRIPS-plus standards.
    Cohen-Kohler JC; Forman L; Lipkus N
    Health Econ Policy Law; 2008 Jul; 3(Pt 3):229-56. PubMed ID: 18634618
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Analysis of the institutional landscape and proliferation of proposals for global vaccine equity for COVID-19: too many cooks or too many recipes?
    Geiger S; McMahon A
    J Med Ethics; 2023 Aug; 49(8):583-590. PubMed ID: 34848492
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Can we move beyond vaccine apartheid? Examining the determinants of the COVID-19 vaccine gap.
    Forman L; Jackson C; Fajber K
    Glob Public Health; 2023 Jan; 18(1):2256822. PubMed ID: 37715686
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Precautionary principle in international law.
    Saladin C
    Int J Occup Environ Health; 2000; 6(4):270-80. PubMed ID: 11114120
    [TBL] [Abstract][Full Text] [Related]  

  • 32. British American Tobacco's tactics during China's accession to the World Trade Organization.
    Zhong F; Yano E
    Tob Control; 2007 Apr; 16(2):133-7. PubMed ID: 17400952
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Global health and Brazilian foreign policy: the negotiations on innovation and intellectual property.
    Lima JHDS
    Cien Saude Colet; 2017 Jul; 22(7):2213-2221. PubMed ID: 28724003
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Intellectual property and access to medicines: mapping public attitudes toward pharmaceuticals during the United States-Mexico-Canada Agreement (USMCA) negotiation process.
    Wong ASY; Cole CB; Kohler JC
    Global Health; 2021 Aug; 17(1):92. PubMed ID: 34416883
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The role of intellectual property rights on access to medicines in the WHO African region: 25 years after the TRIPS agreement.
    Motari M; Nikiema JB; Kasilo OMJ; Kniazkov S; Loua A; Sougou A; Tumusiime P
    BMC Public Health; 2021 Mar; 21(1):490. PubMed ID: 33706726
    [TBL] [Abstract][Full Text] [Related]  

  • 36. What is the impact of intellectual property rules on access to medicines? A systematic review.
    Tenni B; Moir HVJ; Townsend B; Kilic B; Farrell AM; Keegel T; Gleeson D
    Global Health; 2022 Apr; 18(1):40. PubMed ID: 35428250
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Essential medicines and the TRIPS Agreement: collision between the right to health and intellectual property rights].
    Allard Soto R
    Salud Colect; 2015 Mar; 11(1):9-21. PubMed ID: 25853827
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Global governance and the broader determinants of health: A comparative case study of UNDP's and WTO's engagement with global health.
    Gopinathan U; Watts N; Lefebvre A; Cheung A; Hoffman SJ; Røttingen JA
    Glob Public Health; 2019 Feb; 14(2):175-189. PubMed ID: 29848178
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Balancing public health, trade and intellectual monopoly privileges: recent Australian IP legislation and the TPPA.
    Vines T; Crow K; Faunce T
    J Law Med; 2012 Dec; 20(2):280-94. PubMed ID: 23431847
    [TBL] [Abstract][Full Text] [Related]  

  • 40. WTO confidential: the case of asbestos.
    Castleman B
    New Solut; 2003; 13(1):73-85. PubMed ID: 17208721
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.